AKT1 and hepatocellular carcinoma: As aforementioned, AKT overexpression conferred resistance to Lenvatinib in Hep3B and Huh7 cells, however, treatment with SAHA markedly decreased AKT phosphorylation level (Fig. S4E and S4F) and partially restored sensitivity to Lenvatinib (Fig. S5A-5C), which further confirmed AKT inhibition sensitizes HCC cells to Lenvatinib.